Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Needham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report issued on Thursday morning, Benzinga reports. They currently have a $7.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. JMP Securities reaffirmed a market outperform rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Piper Sandler initiated coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an overweight rating and a $9.00 price target on the stock. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, April 30th. Canaccord Genuity Group reiterated a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Finally, Chardan Capital increased their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a buy rating in a research report on Thursday, March 21st. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and a consensus target price of $6.88.

Taysha Gene Therapies Trading Down 0.4 %

Shares of TSHA stock opened at $2.57 on Thursday. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $3.89. The firm’s fifty day simple moving average is $2.65 and its 200 day simple moving average is $2.10. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. Analysts expect that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Citigroup Inc. bought a new position in Taysha Gene Therapies in the 3rd quarter valued at $888,000. FMR LLC raised its holdings in shares of Taysha Gene Therapies by 2,035.0% in the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after buying an additional 23,378,974 shares during the last quarter. EAM Investors LLC bought a new stake in Taysha Gene Therapies during the 3rd quarter worth about $1,060,000. Acuta Capital Partners LLC acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $12,096,000. Finally, Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 235.2% in the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after acquiring an additional 3,738,616 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.